Corin

Cormet

Advanced Hip Resurfacing System 
 


Clinically proven through multi-surgeon, multi-centre data, Cormet shows 96.2%
survivorship at nine years(1). With over 16,000 cementless resurfacings implanted
since 2004, Cormet is clinically-proven fully cementless hip resurfacing(2,3,4).
 

CormetBone conservation

With a choice of cementless or cemented applications, the close
fitting geometry of the Cormet femoral component minimises
the need for bone removal. 
 

Cormet Favourable femoral loading

The polished distal tip of the Cormet resurfacing allows favourable
loading and is designed to minimise stress shielding of the femoral neck.
 
 

Cormet Acetabular stability

The equatorially expanded acetabular component gives excellent
initial stability, with clinically proven Bi-coat and anti-rotational fins
providing excellent primary stability.  
 

Cormet Increased range of motion

Cormet resurfacing and Optimom large diameter articulations provide
stability through a reduced incidence of dislocation and optimised
head-neck ratio, maximising range of motion(2).Cormet
 

Versatility
The implant size range allows the surgeon a range of choices. The resurfacing head diameters are available in 40-56mm in 2mm increments but still allow for two acetabular options for each head, enabling greater intra-operative flexibility.

 

 


References:

1. Unitt L, Bracey D, Fern D, Foguet P, Krikler S, Norton M, Prakash U, Pring D, Spencer R, Vhadra R, Bishay M. The intermediate results of a multi-surgeon, multi-centre cohort using the Cormet hip resurfacing device. BOA 2009:

2. Williams D, Royle M, Norton M. Metal-on-metal resurfacing. The effect of cup position and component size on range of motion to impingement. J Arthroplasty 2009 Jan;24(1):144-51. 

3. Spencer R, Bishay M, Krikler S, Prakash U, Foguet P, Griffin D, Pring D, Norton M, Nelson R. 10 year multi-centre evaluation of the Cormet hip resurfacing arthroplasty. BHS Scientific Meeting, Leeds, UK, 2007. 

4. Cormet hip resurfacing summary of safety and effectiveness, http://www.accessdata.fda.gov/cdrh_docs/pdf5/P050016b.pdf

 
 

 
 


Important: Not all products are available or cleared for distribution in all international markets. For more details, please contact your local subsidiary or distributor by visiting the Corin worldwide section.

 

Print this page Email this page